Allergy seasons are worsening nationwide, and a new report highlights the cities where pollen levels and symptoms are hitting ...

The Asthma and Allergy Foundation of America says more than 106 million people in the United States have allergies and/or ...

Pollen allergy symptoms include: -- Sneezing -- Runny nose and/or stuffy nose -- Itchy nose, eyes, ears, and mouth -- Swelling around the eyes -- Red, watery eyes -- Postnasal drip -- Shortness of ...

Our new study shows that in one of these at-risk communities, children were more likely to develop asthma if their mothers ...

Exposure to “forever chemicals” during pregnancy could increase the risk of childhood asthma, according to new research from ...

Three Bay Area cities, Lakeland, Sarasota, and Tampa all ranked in the top 30 of the 2026 Allergy Capitals report by the Asthma and Allergy Foundation of America (AAFA). USF Health doctors say ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Many people gasp for breath. According to the Allergy and Asthma Foundation of America, over 28 million people in the U.S. have asthma. Unfortunately, it is a leading chronic disease in children. It’s ...

Asthma may not be driven by the molecules scientists have blamed for decades. Researchers have identified “pseudo leukotrienes,” inflammation-triggering compounds formed by uncontrolled free-radical ...

Severe asthma is already treatable with a monthly injectable GSK drug, the blockbuster product Nucala. A new FDA approval gives the drugmaker the opportunity to reach patients with a different ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...